01 November, 2017

Biobanking Expert Robert Hewitt Joins Trans-Hit Bio

Trans-Hit Biomarkers. Inc (THB) is pleased to announce that biobanking expert, Dr. Robert Hewitt, has joined the THB team as Director, Biobank Consortia & Communication. One of his main roles will be to optimize THB’s collaborations with academic biobanks, and enhance the quality and number of interactions between THB’s industrial clients and academic partners.

For the last 7 years, Robert Hewitt (MD PhD) served as the Executive Officer of ESBB (European and Middle Eastern Society for Biopreservation and Biobanking) that he co-founded in 2010. He was also the President of ISBER (International Society for Biological and Environmental Repositories) (2008-2009) and the European Editor of the journal Biopreservation and Biobanking from 2009 to 2016. Previously, Robert also established and/or managed several well-known biobanks: the Integrated Biobank of Luxembourg (IBBL) (2009-2010), the Singapore National University Hospital Tissue Repository and Cancer Registry (2002-2009), the King Faisal Specialist Hospital Tumour Bank (Riyadh, Saudi Arabia) (2000-2001) and the Human Biomaterials Resource Centre at Hammersmith Hospital in London, UK (1998 – 2000). In addition to his unique expertise in Biobanking, Robert also has an in-depth knowledge of biomarker R&D, holding a PhD from the University of Glasgow (Laboratory of Virology) and having completed a Post-Doctoral Fellowship at the National Institutes of Health (NIH – Laboratory of Pathology – Bethesda USA).

Dr. Pascal Puchois, THB CEO said “The incredible contributions Robert has made to the Biobank world make Robert the ideal addition to the THB team to assist in developing the thematic international biobank consortia (e.g. lung cancer) we are starting to build-up to better help our industry partners. Robert’s reputation in the biobanking community is a great asset for us.”

Commenting on his decision, Dr. Robert Hewitt said “I am delighted to join THB, the leading CRO in the biospecimen field and to contribute to the development of disease specific biobank networks aiming to fill the existing gap between biobanks and Industry. I fully endorse THB's Vision regarding the key role that Academic Biobanks should play in the advancement of the biomarker and drug R&D projects of industry that demand not only guarantees of traceability and quality of human biospecimens, not found from most of the usual commercial biospecimen source channels, but also scientific and clinical expertise that Academic Biobanks can offer”.